In this section

Next Steps survivorship program

Survivorship research

The Next Steps Team continues to provide the most current, evidence-based survivorship care for our patients. We are involved in national and international research groups, as well as our own local research efforts. The potential for long term complications, or late effects, after therapy is complete varies for each cancer survivor. Late effects can be physical, effecting the body's organ systems (like heart health or reproductive function), or psycho-social (like fear of recurrence), effecting quality of life. We are working to better understand the risk factors for late effects and learn more about how we can help prevent and treat them in the best way possible. Our research efforts have helped us coordinate care with other sub-specialties (or medical teams) for specialized care, develop Survivorship Care Plans to guide the best and safest care after cancer treatment is complete, and it has positioned us to better understand when supportive resources are needed. We continue to learn from our research to better serve our survivors for them to live happy and healthy lives.

If a full article is needed, please email the research team.

Open for enrollment

Title: Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma

Local primary investigator: Rachel Phelan, MD

Purpose: This study is hoping to determine whether infertility and/or biomarkers of spermatogenesis and steroidogenesis differ in male osteosarcoma survivors treated with cisplatin with or without ifosfamide compared to male controls without a history of cancer. This study also hopes to evaluate whether cisplatin with or without ifosfamide for the treatment of osteosarcoma alters sperm DNA methylation..

Quality of life/outcomes

Fertility

Programmatic

  • Valencia MC, Hang L, Schmidt D, Nichols J, Zhang J, Yan K, Gonzalez A, Schwartz CL, Phelan R. Next Steps: Survivor healthcare passport- A novel form of survivorship care plan in the pediatric population. J Pediatr Hematol Oncol. 2023 Mar 03. PMID: 36898042
  • Bingen, K., Hoag, J., Anderson, L., Chan, S., Gouthro, K.C., Nichols, J., Phelan, R., Schmidt, D., & Karst, J. (2019). Bridge to Next Steps: Evaluation of a transition to survivorship program [Abstract]. Journal of Psychosocial Research & Practice, 1(1S): e11.
  • Karst, J., Hoag, J., Chan, S., Schmidt, D., Anderson, L., Englebert, N., Igler, E., & Bingen, K. (2018, April). Assessment of end-of-treatment transition needs for pediatric cancer and hematopoietic stem cell transplant patients and their families. Pediatr Blood & Cancer.
  • Bingen, K., & Kupst, M.J. (2010, March). Evaluation of a survivorship educational program for adolescent and young adult survivors of childhood cancer.  J Cancer Educ, 25(4), 530-37.  DOI: 10.1007/s13187-010-0077-y.

Medical - BMT

  • Rotz SJ, Bhatt NS, Hamilton BK, Duncan C, Aljurf M, Atsuta Y, Beebe K, Buchbinder D, Burkhard P, Carpenter PA, Chaudhri N, Elemuary M, Elsawy M, Guilcher GM, Hamad N, Karduss A, Peric Z, Purtill D, Rizzo D, Rodrigues M, Ostriz MBR, Salooja N, Schoemans H, Seber A, Sharma A, Srivastava A, Stewart SK, Baker KS, Majhail NS, Phelan R. International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update.  Transplant Cell Ther 2024 Apr;30(4):349-385.
  • Phelan, R., Opeyemi Aremu, T., Karst, J., Anderson, L., Jordan, A., Morin, J., Nichols, J., Singh, A., Schmidt, D., Hoag, J.A., Napurski, C., Zweber, H., & Sada, K.T. (2023). Perspectives on virtual care for childhood cancer survivors in non-metropolitan areas during the COVID-19 pandemic. Current Oncology. doi/10.3390/curroncol30090588
  • Knight B, Anderson L, Lerner D, Phelan R, Thakar MS. Case Series: Development of Polyps as a Late Effect After Total Body Irradiation-based Hematopoietic Cell Transplantation in Children With High-risk Leukemia. J Pediatr Hematol Oncol 2021 Nov 01;43(8):e1159-e1163 PMID: 33828034 PMCID: PMC8492786 SCOPUS ID: 2-s2.0-85120523873 04/09/2021
  • Guilcher GMT, Rivard L, Huang JT, Wright NAM, Anderson L, Eissa H, Pelletier W, Ramachandran S, Schechter T, Shah AJ, Wong K, Chow EJ. Immune function in childhood cancer survivors: a Children's Oncology Group review. Lancet Child Adolesc Health 2021 Apr;5(4):284-294 PMID: 33600774 PMCID: PMC8725381 SCOPUS ID: 2-s2.0-85102642258 02/19/2021
  • Kahn JM, Brazauskas R, Tecca HR, Bo-Subait S, Buchbinder D, Battiwala M, Flowers MED, Savani BN, Phelan R, Broglie L, Abraham AA, Keating AK, Daly A, Wirk B, George B, Alter BP, Ustun C, Freytes CO, Beitinjaneh AM, Duncan C, Copelan E, Hildebrandt GC, Murthy HS, Lazarus HM, Auletta JJ, Myers KC, Williams KM, Page KM, Vrooman LM, Norkin M, Byrne M, Diaz MA, Kamani N, Bhatt NS, Rezvani A, Farhadfar N, Mehta PA, Hematti P, Shaw PJ, Kamble RT, Schears R, Olsson RF, Hayaski RJ, Gale RP, Mayo SJ, Schhabra S, Rotz SJ, Badawy SM, Ganguly S, Pavletic S, Nishihori T, Prestidge T, Agrawal V, Hogan WJ, Inamoto Y, Shaw BE, Satwani P. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Adv. 2020 May 12;4(9):2084-2094.
  • Scheuermann A, Phelan R, Browning M. Development of Secondary Osteosarcoma After TBI and Allogeneic Bone Marrow Transplant: A Case Series of 3 Patients. J Pediatr Hematol Oncol. 2020 Mar;42(2):e100-e103
  • Lee CJ, Kim S, Tecca HR, Bo-Subait S, Phelan R, Brazauskas R, Buchbinder D, Hamilton BK, Battiwalla M, Majhail NS, Lazarus HM, Shaw PJ, Marks DI, Litzow MR, Chhabra S, Inamoto Y, DeFilipp Z, Hildebrandt GC, Olsson RF, Kasow KA, Liesveld JL, Rotz SJ, Badawy SM, Bhatt NS, Yared JA, Page KM, Arellano ML, Kent M, Farhadfar N, Seo S, Hematti P, Freytes CO, Rovó A, Ganguly S, Nathan S, Burns L, Shaw BE, Muffly LS. Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Adv. 2020 Mar 24;4(6):983-992. PMCID: PMC70940
  • Bhatt NS, Brazauskas R, Tecca HR, Carreras J, Burns LJ, Phelan R, Salit RB, Syrjala KL, Talano JM, Shaw BE. Post-transplantation employment status of adult survivors of childhood allogeneic hematopoietic cell transplant: A report from the Center for International Blood and Marrow Transplant Research (CIBMTR). Cancer. 2019 01 01;125(1):144-152. PMCID: PMC6310211
  • Pierpont EI, McCoy E, King KE, Ziegler RS, Shanley R, Nascene D, Raymond GV, Phelan R, Lund TC, Orchard PJ, Miller WP. Post-transplant adaptive function in childhood cerebral adrenoleukodystrophy. Ann Clin Transl Neurol. 2018 03;5(3):252-261. PMCID: PMC5846389
  • Chow EJ, Anderson L, Baker KS, Bhatia S, Guilcher GM, Huang JT, Pelletier W, Perkins JL, Rivard LS, Schechter T, Shah AJ, Wilson KD, Wong K, Grewal SS, Armenian SH, Meacham LR, Mulrooney DA, Castellino SM. Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report.  Biol Blood Marrow Transplant 2016 May;22(5):782-95 PMID: 26802323 PMCID: PMC4826622 SCOPUS ID: 2-s2.0-84963656324 01/24/2016
  • Anderson L, Gregg D, Margolis D, Casper J, Talano J. Focal nodular hyperplasia in pediatric allogeneic hematopoietic cell transplant: case series. Bone Marrow Transplant 2010 Aug;45(8):1357-9 PMID: 20140023 SCOPUS ID: 2-s2.0-77955561931 02/09/2010
  • Anderson, L., Schmidt, D., Bingen, K., Kupst, M.J., & Warwick, A. (2009, Nov-Dec). Growth velocity in pediatric bone marrow transplantation: Significance of donor type and treatment factors, J Pediatr Oncol Nurs, 26 (6), 377-382.  PMID: 20032299.

Medical - Oncology